1. Brahm M. Subcutaneous treatment with recombinant human erythropoietin—the influence of injection frequency and skin-fold thickness. Scand J Urol Nephrol. 1999;33(3):192–6.
2. Iino Y, Goto T, Koyabu S, Katsuji T, Tanaka K, Hisanaga S, Yamamoto T, Gejyo H, Nishi S, Suzuki M, Akiba T, Saito A, Watanabe Y, Hirakata H, Uchida E, Tsubakihara E, Akizawa T. The pharmacokinetics of KRN321 (darbepoetin alfa) in chronic kidney disease patients not on dialysis after single intravenous administration. Kidney Dial. 2010;68(1):121–6 (in Japanese).
3. Iino Y, Taguma Y, Asano Y, Kusano E, Suzuki H, Hosoya T, Deura T, Nagashima S, Tsubakihara Y, Hiramatsu M, Hori K, Gejyo H, Nishi S, Suzuki M, Akiba T, Saito A, Watanabe Y, Hirakata H, Uchida E, Akizawa T, Koshikawa S. Pharmacokinetics of KRN321 (darbepoetin alfa) in continuous ambulatory peritoneal dialysis patients and in chronic kidney disease patients not on dialysis after subcutaneous administration. Kidney Dial. 2010;68(1):111–20 (in Japanese).
4. Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (EPO) in view of the pharmacokinetics of the recombinant drugs rHuEPO and NESP. Eur J Haematol. 2002;69:265–74.
5. Jensen JD, Jensen LW, Madsen JK. The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur J Clin Pharmacol. 1994;46:333–7.